[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58-60.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
　Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(01):58-60.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
点击复制

肾上腺醛固酮腺瘤术后临床转归的影响因素()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年01期
页码:
58-60
栏目:
综述
出版日期:
2016-01-20

文章信息/Info

Title:
Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma
作者:
高海静; 温俊平
350000 福州,福建中医药大学,福建省立医院内分泌科,福建省立医院内分泌研究室
Author(s):
Gao Haijing; Wen Junping.
Fujian University of Traditional Chinese Medicine, Department of Endocrinology,Fujian Provincial Hospital, Endocrine Laboratory of Fujian Provincial Hospital Fuzhou 350000,China
关键词:
原发性醛固酮增多症;  单侧肾上腺皮质腺瘤;  醛固酮腺瘤
Keywords:
Primary aldosteronism;  Unilateral adrenocortical adenoma;  Aldosteronoma
DOI:
10.3760/cma.j.issn.1673-4157.2016.01.015
摘要:
肾上腺醛固酮腺瘤是原发性醛固酮增多症的一种常见类型,一般对单侧肾上腺醛固酮腺瘤的治疗方案是进行手术切除。经手术治疗可以降低高血压,影响术后血压恢复的因素有年龄、高血压持续时间、肾功能、基因型和醛固酮受体拮抗剂敏感,但也可以在术后并发高钾血症和慢性肾脏疾病,引起术后发生高钾血症的因素有高血压持续时间和肾小球滤过率,引起术后发生慢性肾脏疾病的因素有术前肾小球滤过率和醛固酮肾素比值。因此,应该对单侧肾上腺醛固酮腺瘤手术治疗的患者进行全方面的评估,以避免术后并发症的发生。
Abstract:
Adrenal aldosteronoma is one of the common types of primary aldosteronism and the treatment of unilateral adrenal aldosterone tumor is surgical resection.Surgical treatment can reduce blood pressure.The influence factors of postoperative blood pressure are age, duration of high blood pressure, kidney function,genotype and sensitivity of aldosterone receptor antagonist.But surgery can also be complicated with hyperkalemia and chronic kidney disease.Hyperkalemia occurred after surgery greatly influenced by factors of high blood pressure and glomerular filtration rate.Postoperative chronic kidney disease greatly influenced by the factors of preoperative glomerular filtration rate and aldosterone renin ratio.Therefore,patients with unilateral adrenal aldosteronoma need all aspects of evaluation before surgery, in order to avoid the occurrence of postoperative complications.

参考文献/References:

[1] Mulatero P,Monticone S,Bertello C,et al. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism[J].J Clin Endocrinol Metab,2013,98(12):4826-4833. DOI: 10.1210/jc.2013-2805.
[2] Sechi LA,Colussi G,Di Fabio A,et al. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment[J].Am J Hypertens,2010,23(12):1253-1260.DOI:10.1038/ajh.2010.169.
[3] Zhang X,Zhu Z,Xu T,et al. Factors affecting complete hypertension cure after adrenalectomy for aldosterone-producing adenoma:outcomes in a large series[J].Urol Int,2013,90(4):430-434. DOI:10.1159/000347028.
[4] van der Linden P,Steichen O,Zinzindohoué F,et al. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study[J].J Hypertens,2012,30(4):761-769.DOI:10.1097/HJH.0b013e328350225d.
[5] Utsumi T,Kawamura K,Imamoto T,et al. Assessment of postoperative changes in antihypertensive drug consumption in patients with primary aldosteronism using the defined daily dose[J].Asian J Surg,2014,37(4):190-194. DOI:10.1016/j.asjsur.2014.01.011.
[6] Wang W,Hu W,Zhang X,et al.Predictors of successful outcome after adrenalectomy for primary aldosteronism[J].Int Surg,2012,97:104-111.
[7] Ip JC,Pang TC,Pon CK,et al. Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism[J].ANZ J Surg,2015,85(4):279-283. DOI:10.1111/ans.12470.
[8] Muth A,Ragnarsson O,Johannsson G,et al. Systematic review of surgery and outcomes in patients with primary aldosteronism[J].Br J Surg,2015,102(4):307-317.DOI:10.1002/bjs.9744.
[9] Chao CT,Wu VC,Kuo CC,et al. Diagnosis and management of primary aldosteronism: an updated review[J].Ann Med,2013,45(4):375-383.DOI: 10.3109/07853890.2013.785234.
[10] Huang WT,Chau T,Wu ST,et al. Prolonged hyperkalemia following unilateral adrenalectomy for primary hyperaldosteronism[J].Clin Nephrol,2010,73(5):392-397.
[11] Hibi Y,Hayakawa N,Hasegawa M,et al. Unmasked renal impairment and prolonged hyperkalemia after unilateral adrenalectomy for primaryaldosteronism coexisting with primary hyperparathyroidism: report of a case[J].Surg Today,2015,45(2):241-246. DOI:10.1007/s00595-013-0813-0.
[12] Chiang WF,Cheng CJ,Wu ST,et al. Incidence and factors of post-adrenalectomy hyperkalemia in patients with aldosterone producing adenoma[J].Clin Chim Acta,2013,424:114-118. DOI:10.1016/j.cca.2013.05.017.
[13] Fischer E,Hanslik G,Pallauf A,et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy[J].J Clin Endocrinol Metab,2012,97(11):3965-3973. DOI:10.1210/jc.2012-2234.
[14] Iwakura Y,Morimoto R,Kudo M,et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases[J].J Clin Endocrinol Metab,2014,99(5):1593-1598. DOI:10.1210/jc.2013-2180.
[15] Park KS,Kim JH,Ku EJ,et al. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma[J]. Eur J Endocrinol,2015,172(6):725-731. DOI:10.1530/EJE-15-0074.
[16] Fourkiotis V,Vonend O,Diederich S,et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism[J].Eur J Endocrinol,2012,168(1):75-81. DOI:10.1530/EJE-12-0631.
[17] Tanase-Nakao K,Naruse M,Nanba K,et al. Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism[J].Clin Endocrinol(Oxf),2014,81(5):665-670. DOI:10.1111/cen.12497.
[18] Utsumi T,Kawamura K,Imamoto T,et al. Preoperative masked renal damage in Japanese patients with primary aldosteronism:identification of predictors for chronic kidney disease manifested after adrenalectomy[J].Int J Urol,2013,20(7):685-691. DOI:10.1111/iju.12029.

相似文献/References:

[1]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
　Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(01):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
[2]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
　Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(01):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[3]王慧萍,童安莉.原发性醛固酮增多症相关的基因突变研究进展[J].国际内分泌代谢杂志,2021,41(02):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
　Wang Huiping,Tong Anli..Research progress on gene mutation related primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(01):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
[4]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
　Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(01):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
[5]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
　Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(01):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
[6]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
　Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(01):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
[7]王敏 杨宇宏 孙敏.原发性醛固酮增多症的组织病理学新分类及其意义[J].国际内分泌代谢杂志,2023,43(05):372.[doi:10.3760/cma.j.cn121383-20220604-06010]
　Wang Min,Yang Yuhong,Sun Min..New histopathological classification of primary aldosteronism and its significance[J].International Journal of Endocrinology and Metabolism,2023,43(01):372.[doi:10.3760/cma.j.cn121383-20220604-06010]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81170774); 福建省科技厅科技引导性项目(2015Y0008); 福建省卫生系统中青年骨干人才培养项目资助计划(2014-ZQN-ZD-1)
更新日期/Last Update: 2016-01-20